Antiretroviral therapy and efficacy after virologic failure on first-line boosted protease inhibitor regimens - Wikidata - wikimedia - TriplyDB

Antiretroviral therapy and efficacy after virologic failure on first-line boosted protease inhibitor regimens

Antiretroviral therapy and efficacy after virologic failure on first-line boosted protease inhibitor regimens

http://www.wikidata.org/entity/Q34137798

about

HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance Testing HIV-1 drug resistance and resistance testing.Randomized trial of stopping or continuing ART among postpartum women with pre-ART CD4 ≥ 400 cells/mm3.Treatment Outcomes and Resistance Patterns of Children and Adolescents on Second-Line Antiretroviral Therapy in Asia Outcomes after viral load rebound on first-line antiretroviraltreatment in children with HIV in the UK and Ireland: an observational cohort study Evolution of gag and gp41 in Patients Receiving Ritonavir-Boosted Protease Inhibitors.Antiretroviral changes during the first year of therapy.Human Immunodeficiency Virus Type 1 Drug Resistance Mutations Update.The Clinical and Economic Impact of Attaining National HIV/AIDS Strategy Treatment Targets in the United States.

P2860

Q28271593-F1830EA0-17CF-46A1-B0D7-F7AB98FC08BA Q30245693-782A7D5D-8904-4C24-B42A-8046B7DD006E Q33657188-21F20D50-502D-4916-969E-9895D34267A5 Q36063912-C4A7E5B4-921E-4244-B86C-414BFC12B79F Q36087922-D343E8EB-BB90-4D41-87EE-65416D377ED6 Q40039995-8586B949-BC5E-4589-8A5F-C31D96D5C4C2 Q41924662-E7C9A96B-9EBB-467C-BC6A-72C8F44A576B Q41926589-AF462920-D96E-4E0A-91B1-51AB950E99FD Q47549535-C0B4EEFD-1BEE-4DA8-A385-B5D7840F52CC

P2860

Antiretroviral therapy and efficacy after virologic failure on first-line boosted protease inhibitor regimens

http://www.wikidata.org/entity/Q34137798

description

2014 nî lūn-bûn

@nan

2014 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Antiretroviral therapy and eff ...... ed protease inhibitor regimens

@ast

Antiretroviral therapy and eff ...... ed protease inhibitor regimens

@en

Antiretroviral therapy and eff ...... ed protease inhibitor regimens

@nl

type

label

Antiretroviral therapy and eff ...... ed protease inhibitor regimens

@ast

Antiretroviral therapy and eff ...... ed protease inhibitor regimens

@en

Antiretroviral therapy and eff ...... ed protease inhibitor regimens

@nl

prefLabel

Antiretroviral therapy and eff ...... ed protease inhibitor regimens

@ast

Antiretroviral therapy and eff ...... ed protease inhibitor regimens

@en

Antiretroviral therapy and eff ...... ed protease inhibitor regimens

@nl

P1433

Q34137798-47972F7E-805D-475C-97D7-1E3303449DF8

P1476

Q34137798-A4CDB423-A812-4F84-AB19-F0F8A19BA8D1

P2093

Q34137798-1B7D7058-3D40-4302-A624-BABFE7A9289C

Q34137798-1BDD24CE-627F-4297-94DD-F9F6C4DF1BE3

Q34137798-2F4C6714-32A8-4404-8B69-D767E438E6ED

Q34137798-4E789B3C-90FF-48AA-A677-B2CFEAEE26B3

Q34137798-517D06D8-8AB4-4CD2-B48F-CCCF244617F6

Q34137798-728773DA-19E5-4C31-BEE8-B9931E9B7312

Q34137798-73F4DD9D-363D-4F26-81CB-1B616322520E

Q34137798-8354B778-68CE-48B6-8745-EBA319D4DF53

Q34137798-9EB5B7DA-59D0-4C1E-9B10-A23D15E7D756

Q34137798-AE49D4E7-C29C-4D51-BCF6-3AFABB33C1E6

P2860

Q34137798-06831FBB-AA2C-4F3C-BDCA-777987DF0DE1

Q34137798-11FB07AF-CF80-4D6E-9215-A8932526B3B2

Q34137798-121E61DA-66D7-44C8-8758-3000AACE83CF

Q34137798-1CA2C193-335C-4C4A-B7E0-23283BFB1555

Q34137798-2893C497-B184-49A2-A4B7-7FECF2304E2B

Q34137798-2A208F75-4B08-4394-8BEE-FB19FB881B69

Q34137798-4493C3EE-839A-4061-B653-5D36CA43F483

Q34137798-549B9D44-CEC4-40FE-881A-2E3F7A44FF64

Q34137798-57DB4302-3603-4D88-A09E-2FDDC5CA02B7

Q34137798-6743BADC-BF0B-4BA6-B3E4-AA7DDFF565C9

P304

Q34137798-26D005C5-463F-4AE8-A491-67EC1A4E617E

P31

Q34137798-1C12FDE2-9868-4CEE-9F8A-BAF181C63813

P356

Q34137798-14714DFF-A8AF-470C-85B8-9DA8EE3072B9

P407

Q34137798-08F85A6C-DAF6-430A-8498-1E90C7169249

P433

Q34137798-1AA56470-9F96-4E0D-90B5-96397512042A

P478

Q34137798-F11B1591-CA1E-4C66-BE03-A7E55E9D7944

P50

Q34137798-E4AD1168-1943-4241-A891-98B3BC1FDBC1

P577

Q34137798-2318E8C3-5053-4551-8D80-E1F57F67E6BA

P5875

Q34137798-5E76CD39-3C9C-4BA6-9C19-8025939D1775

P698

Q34137798-929D1CBA-2872-4473-BC3E-F85E0CBCFA14

P921

Q34137798-3A85C873-FD21-46C9-8B40-EA882565AD6B

Q34137798-A420283D-24CD-4ABA-8455-2A95202F564D

P932

Q34137798-BE7DACD2-478E-4ED7-8289-F2179FB9137C

P356

P1433

Clinical Infectious Diseases

P1476

Antiretroviral therapy and eff ...... ed protease inhibitor regimens

@en

P2093

Constance A Benson

http://www.w3.org/2001/XMLSchema#string

Eric S Daar

http://www.w3.org/2001/XMLSchema#string

Judith S Currier

http://www.w3.org/2001/XMLSchema#string

Michael D Hughes

http://www.w3.org/2001/XMLSchema#string

Mina C Hosseinipour

http://www.w3.org/2001/XMLSchema#string

Paul E Sax

http://www.w3.org/2001/XMLSchema#string

Richard Haubrich

http://www.w3.org/2001/XMLSchema#string

Robert A Salata

http://www.w3.org/2001/XMLSchema#string

Roy M Gulick

http://www.w3.org/2001/XMLSchema#string

Sharon A Riddler

http://www.w3.org/2001/XMLSchema#string

P2860

Virologic failures on initial boosted-PI regimen infrequently possess low-level variants with major PI resistance mutations by ultra-deep sequencing

Nevirapine- versus lopinavir/ritonavir-based initial therapy for HIV-1 infection among women in Africa: a randomized trial

Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel.

Antiretroviral therapies in women after single-dose nevirapine exposure.

Protease Inhibitor Resistance Is Uncommon in HIV-1 Subtype C Infected Patients on Failing Second-Line Lopinavir/r-Containing Antiretroviral Therapy in South Africa

Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance.

Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1.

Antiretroviral dynamics determines HIV evolution and predicts therapy outcome.

Long-term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen modification

Second-line antiretroviral therapy: long-term outcomes in South Africa.

P304

888-896

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/CID/CIU367

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

59

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-05-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262536792

http://www.w3.org/2001/XMLSchema#string

P698

24842909

http://www.w3.org/2001/XMLSchema#string

P921

antiretroviral drug

P932

4155445

http://www.w3.org/2001/XMLSchema#string